A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

NCT02497378 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: JNJ-54767414 (Daratumumab)
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Janssen Pharmaceutical K.K.